The closest thing here to a prescription drug
These pages usually compare a research chemical against the prescription route it will never have. Cagrilintide is the case where the comparison is genuinely tight, because the compound is on that route right now.
Around 45 registered studies, 22 of them Phase 3, roughly 25 completed, ten recruiting and seven active but not recruiting. Novo Nordisk is lead sponsor on all of them. That is a pharmaceutical development programme in its final phase, not a peptide with a forum following.
What it still lacks, and why it matters
No approval. No label. No authorised quantity. No pharmacy that can dispense it against a prescription.
The distinction is easy to lose because a late-stage programme looks so much like the finished article. But the last step, a regulator reading the full dossier and being accountable for the conclusion, is the one that converts trial evidence into an authorised dose, and it has not happened.
Until it does, every figure in circulation is a trial quantity: real, measured, published, and attached to a protocol rather than to a prescriber.
One sponsor, one combination, two things to check
Every registered study has the same lead sponsor. During development that is normal, and it also means no independent group has replicated any of it. Worth stating whenever a figure travels outside the programme.
The second check is the combination. The registered work pairs cagrilintide with semaglutide, as CagriSema. The search phrase people actually use often asks about cagrilintide with tirzepatide, which is a different pairing these trials did not study. Partner drugs differ in mechanism, half-life and titration, so a quantity established alongside one is not a quantity for the other.
A cagrilintide dosage chart that names the trial, the partner drug and the approval status is reporting accurately. One that prints a number alone has dropped everything that determines whether it applies.